{"disease":{"id":"thrombin","name":"thrombin"},"drugs":{"marketed":[{"drug_id":"vitamin-k1","indication_name":"Anticoagulant-induced prothrombin deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin K1","generic_name":"Phytonadione","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects)","drug_class":"Vitamin K [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"vitamin-k1","indication_name":"Hypoprothrombinemia due to antibacterial therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin K1","generic_name":"Phytonadione","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects)","drug_class":"Vitamin K [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"vitamin-k1","indication_name":"Hypoprothrombinemia due to absorption or synthesis issues","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin K1","generic_name":"Phytonadione","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects)","drug_class":"Vitamin K [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"vitamin-k1","indication_name":"Other drug-induced hypoprothrombinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin K1","generic_name":"Phytonadione","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects)","drug_class":"Vitamin K [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"phytonadione","indication_name":"Anticoagulant-induced prothrombin deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PHYTONADIONE","company_name":"","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1 (VKORC1)","drug_class":"Vitamin K [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"phytonadione","indication_name":"Hypoprothrombinemia due to antibacterial therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PHYTONADIONE","company_name":"","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1 (VKORC1)","drug_class":"Vitamin K [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"phytonadione","indication_name":"Hypoprothrombinemia due to absorption or synthesis limitations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PHYTONADIONE","company_name":"","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1 (VKORC1)","drug_class":"Vitamin K [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"phytonadione","indication_name":"Drug-induced hypoprothrombinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PHYTONADIONE","company_name":"","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1 (VKORC1)","drug_class":"Vitamin K [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"vitamin-k1","indication_name":"Anticoagulant-induced prothrombin deficiency caused by coumarin derivatives","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin K1","generic_name":"Phytonadione","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects)","drug_class":"Vitamin K [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"vitamin-k1","indication_name":"Anticoagulant-induced prothrombin deficiency caused by indanedione derivatives","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin K1","generic_name":"Phytonadione","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects)","drug_class":"Vitamin K [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"vitamin-k1","indication_name":"Hypoprothrombinemia due to antibacterial therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin K1","generic_name":"Phytonadione","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects)","drug_class":"Vitamin K [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"vitamin-k1","indication_name":"Hypoprothrombinemia secondary to obstructive jaundice","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin K1","generic_name":"Phytonadione","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects)","drug_class":"Vitamin K [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"vitamin-k1","indication_name":"Hypoprothrombinemia secondary to biliary fistula","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin K1","generic_name":"Phytonadione","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects)","drug_class":"Vitamin K [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"vitamin-k1","indication_name":"Hypoprothrombinemia secondary to sprue","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin K1","generic_name":"Phytonadione","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects)","drug_class":"Vitamin K [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"vitamin-k1","indication_name":"Hypoprothrombinemia secondary to ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin K1","generic_name":"Phytonadione","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects)","drug_class":"Vitamin K [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"vitamin-k1","indication_name":"Hypoprothrombinemia secondary to celiac disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin K1","generic_name":"Phytonadione","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects)","drug_class":"Vitamin K [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"vitamin-k1","indication_name":"Hypoprothrombinemia secondary to intestinal resection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin K1","generic_name":"Phytonadione","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects)","drug_class":"Vitamin K [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"vitamin-k1","indication_name":"Hypoprothrombinemia secondary to cystic fibrosis of the pancreas","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin K1","generic_name":"Phytonadione","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects)","drug_class":"Vitamin K [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"vitamin-k1","indication_name":"Hypoprothrombinemia secondary to regional enteritis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin K1","generic_name":"Phytonadione","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects)","drug_class":"Vitamin K [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"vitamin-k1","indication_name":"Drug-induced hypoprothrombinemia caused by salicylates","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin K1","generic_name":"Phytonadione","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Vitamin K-dependent carboxylase; vitamin K epoxide reductase complex (indirect antagonism of warfarin effects)","drug_class":"Vitamin K [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"phytomenadione","indication_name":"Antibiotic-Induced Hypoprothrombinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"phytomenadione","company_name":"Instituto Mexicano del Seguro Social","drug_phase":"phase_2","molecular_target":"Alpha-synuclein","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"phytomenadione","indication_name":"Anticoagulant-Induced Prothrombin Deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"phytomenadione","company_name":"Instituto Mexicano del Seguro Social","drug_phase":"phase_2","molecular_target":"Alpha-synuclein","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"phytomenadione","indication_name":"Vitamin K Deficiency Induced Hypoprothrombinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"phytomenadione","company_name":"Instituto Mexicano del Seguro Social","drug_phase":"phase_2","molecular_target":"Alpha-synuclein","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"phytonadione","indication_name":"Anticoagulant-induced prothrombin deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PHYTONADIONE","company_name":"","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1 (VKORC1)","drug_class":"Vitamin K [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"phytonadione","indication_name":"Hypoprothrombinemia due to antibacterial therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PHYTONADIONE","company_name":"","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1 (VKORC1)","drug_class":"Vitamin K [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"phytonadione","indication_name":"Hypoprothrombinemia secondary to factors limiting absorption or synthesis of Vitamin K","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PHYTONADIONE","company_name":"","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1 (VKORC1)","drug_class":"Vitamin K [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"phytonadione","indication_name":"Other drug-induced hypoprothrombinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PHYTONADIONE","company_name":"","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1 (VKORC1)","drug_class":"Vitamin K [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"phylloquinone","indication_name":"Antibiotic-Induced Hypoprothrombinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Phylloquinone","company_name":"Guy's and St Thomas' NHS Foundation Trust","drug_phase":"phase_2","molecular_target":"Alpha-synuclein","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"phylloquinone","indication_name":"Anticoagulant-Induced Prothrombin Deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Phylloquinone","company_name":"Guy's and St Thomas' NHS Foundation Trust","drug_phase":"phase_2","molecular_target":"Alpha-synuclein","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"phylloquinone","indication_name":"Vitamin K Deficiency Induced Hypoprothrombinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Phylloquinone","company_name":"Guy's and St Thomas' NHS Foundation Trust","drug_phase":"phase_2","molecular_target":"Alpha-synuclein","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":30,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04912193","title":"Antithrombin III and Post-liver Transplantation Acute Kidney Injury","phase":"","overall_status":"COMPLETED","enrollment_count":2395,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT05123326","title":"Global Coagulation Assessment in Portal Vein Thrombosis and Budd-Chiari Syndrome","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Post Graduate Institute of Medical Education and Research, Chandigarh","has_results":false},{"nct_id":"NCT04762576","title":"Thrombin in Cardiac Surgery","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT04356950","title":"Analysis of the Coagulopathy Developed by COVID-19 Infected Patients","phase":"","overall_status":"COMPLETED","enrollment_count":175,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nīmes","has_results":false},{"nct_id":"NCT07276074","title":"Evaluation of the Relevance of Antithrombin Prescriptions at Strasbourg University Hospitals","phase":"","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"University Hospital, Strasbourg, France","has_results":false},{"nct_id":"NCT02833025","title":"Point-of-care Assessment of Thrombin Generation and Platelet Function in Children Requiring Cardiopulmonary Bypass","phase":"","overall_status":"UNKNOWN","enrollment_count":130,"lead_sponsor_name":"The Hospital for Sick Children","has_results":false},{"nct_id":"NCT06395480","title":"Albumin Utilization in Adult Cardiac Surgical Patients : A Multicentre Prospective Cohort Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":104,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT04762550","title":"Thrombin Generation in Liver Transplant Surgery","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT03064035","title":"Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":79,"lead_sponsor_name":"HealthPartners Institute","has_results":true},{"nct_id":"NCT06543849","title":"The Impact of Targeted Temperature Management Duration on Thrombin Function in Cardiac Arrest Patients","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":64,"lead_sponsor_name":"Tang Ziren","has_results":false},{"nct_id":"NCT01159210","title":"Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT04899232","title":"Antithrombin III in Infectious Disease Caused by COVID-19","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":52,"lead_sponsor_name":"Enrique Ginzburg","has_results":true},{"nct_id":"NCT04879550","title":"Prospective Investigation of Antithrombin III Deficiency in Adult Patients With ECMO","phase":"","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital","has_results":false},{"nct_id":"NCT04918173","title":"Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":38,"lead_sponsor_name":"Octapharma","has_results":false}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}